From Wikipedia, the free encyclopedia
Jump to: navigation, search
Saroglitazar skeletal.svg
Clinical data
Trade names Lipaglyn
  • C
Routes of
ATC code
  • None
Legal status
Legal status
  • Approved in India
CAS Number
PubChem CID
Chemical and physical data
Formula C25H29NO4S
Molar mass 439.56 g/mol
3D model (Jmol)

Saroglitazar (INN, trade name Lipaglyn) is a drug for the treatment of type 2 diabetes mellitus and dyslipidemia. It is approved for use in India by the Drug Controller General of India.[1] Saroglitazar is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In clinical studies, saroglitazar has demonstrated reduction of triglycerides (TG), LDL cholesterol, VLDL cholesterol, non-HDL cholesterol and an increase in HDL cholesterol a characteristic hallmark of atherogenic diabetic dyslipidemia (ADD). It has also shown favorable Anti-diabetic medication property by reducing the fasting plasma glucose and HBA1c in diabetes patients. The recommended dose of saroglitazar is one tablet of 4 mg once a day.

Mechanism of action[edit]

Saroglitazar is novel first in class drug which acts as a dual PPAR agonist at the subtypes α (alpha) and γ (gamma) of the peroxisome proliferator-activated receptor (PPAR). Agonist action at PPARα lowers high blood triglycerides, and agonist action on PPARγ improves insulin resistance and consequently lowers blood sugar.[2]


Being a dual PPAR agonist, Saroglitazar (Lipaglyn) helps in controlling blood glucose and Lipid parameters especially high triglycerides and high non HDL-Cholesterol.[3] Lipaglyn effectively reduces triglycerides and non HDL-C and controlles high blood sugar, a typical situation in Insulin Resistance condition.[4][5]


Saroglitazar has not demonstrated any of the adverse effects like weight gain and edema that are usually identified with similar molecules like the glitazone class of drugs.[6] Because it is an insulin sensitizer, Saroglitazar (Lipaglyn) has less potential for hypoglycemia. No major serious adverse events have been reported; however, long-term cardiovascular safety has not been established.[7]


  1. ^ "Zydus Group launches new diabetic drug". The Times of India. Jun 6, 2013. 
  2. ^ "Lipaglyn (Saroglitazar) for Treating Hypertriglycerdemia in Type II Diabetes, India". Drug Development and Technology. 
  3. ^ Manoria, PC; Chopra, HK; Parashar, SK; Dutta, AL; Pinto, B; Mullasari, A; Prajapati, S. "The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.". Indian Heart Journal. 65 (6): 683–90. doi:10.1016/j.ihj.2013.10.015. PMC 3905264Freely accessible. PMID 24407538. 
  4. ^ "Observational Study of Effects of Saroglitazar on Glycaemic and Lipid Parameters on Indian Patients with Type 2 Diabetes". SCIENTIFIC REPORTS. 
  5. ^ Ramakrishnan, S. "From 'Make in India' to 'Made in India': the saroglitazar story.". Indian Heart Journal. 67 (1): 8–10. doi:10.1016/j.ihj.2015.02.014. PMC 4382552Freely accessible. PMID 25820041. 
  6. ^ Shetty, SR; Kumar, S; Mathur, RP; Sharma, KH; Jaiswal, AD. "Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients.". Indian Heart Journal. 67 (1): 23–6. doi:10.1016/j.ihj.2015.02.007. PMC 4382542Freely accessible. PMID 25820046. 
  7. ^ Munigoti, SrinivasaP; Harinarayan, CV (2014). "Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?". Indian Journal of Endocrinology and Metabolism. 18 (3): 283–7. doi:10.4103/2230-8210.131134. PMC 4056123Freely accessible. PMID 24944919.